You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
25 June 2026 - Biosidus, an Argentina-based biotechnology company, announced on Wednesday the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biolog...
25 June 2026 - Clinical-stage biopharmaceutical company Vascarta Inc announced on Wednesday the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor; topical curcumin gel) for the treatment of sickle...
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
25 June 2026 - Cirius Therapeutics Inc, a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, announced on Wednesday that enrolment and dosing has begun in a Phase 2 clinica...
24 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Wednesday that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colore...
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead RNA therapeutic candidate, miRisten, for Acute My...
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without ...
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorisation for Wayrilz (rilzabrutinib), an...